

Andr s Finzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4785644/publications.pdf>

Version: 2024-02-01

171
papers

10,217
citations

38660

50
h-index

49773

87
g-index

212
all docs

212
docs citations

212
times ranked

10796
citing authors

#	ARTICLE	IF	CITATIONS
1	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Host and Microbe</i> , 2022, 30, 97-109.e5.	5.1	83
2	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. <i>Cell Reports</i> , 2022, 38, 110210.	2.9	96
3	Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4 ⁺ T Cell. <i>Journal of Virology</i> , 2022, 96, jvi0192921.	1.5	10
4	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110368.	2.9	82
5	B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. <i>Vaccine</i> , 2022, 40, 1203-1207.	1.7	11
6	Standardization of a flow cytometry SARS-CoV-2 serologic test. <i>Cytotechnology</i> , 2022, 74, 99-103.	0.7	1
7	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. <i>PLoS Pathogens</i> , 2022, 18, e1010183.	2.1	8
8	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. <i>Viruses</i> , 2022, 14, 144.	1.5	12
9	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Reports</i> , 2022, 38, 110429.	2.9	50
10	SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells. <i>Viruses</i> , 2022, 14, 5.	1.5	16
11	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
12	Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 532.	1.5	17
13	Seroprevalence of SARS-CoV-2 antibodies among blood donors in Quebec: an update from a serial cross-sectional study. <i>Canadian Journal of Public Health</i> , 2022, 113, 385-393.	1.1	3
14	Novel Compound Inhibitors of HIV-1NL4-3 Vpu. <i>Viruses</i> , 2022, 14, 817.	1.5	2
15	Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies. <i>MBio</i> , 2022, 13, e0057722.	1.8	5
16	Covid-19 vaccine immunogenicity in people living with HIV-1. <i>Vaccine</i> , 2022, 40, 3633-3637.	1.7	47
17	VE607 stabilizes SARS-CoV-2 Spike in the RBD-up conformation and inhibits viral entry. <i>IScience</i> , 2022, 25, 104528.	1.9	8
18	SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity. <i>Viruses</i> , 2022, 14, 1237.	1.5	10

#	ARTICLE	IF	CITATIONS
19	Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
20	The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
21	Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. <i>Science Advances</i> , 2022, 8, .	4.7	27
22	Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	25
23	Editorial: Exploring Novel Approaches to Eliminate HIV Reservoirs to Achieve a Cure for HIV. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 658848.	1.8	0
24	High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. <i>Transfusion</i> , 2021, 61, 1377-1382.	0.8	17
25	Stabilizing the HIV-1 Envelope Glycoprotein State 2A Conformation. <i>Journal of Virology</i> , 2021, 95, .	1.5	9
26	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
27	Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. <i>Cell Reports</i> , 2021, 34, 108790.	2.9	94
28	The great escape? SARS-CoV-2 variants evading neutralizing responses. <i>Cell Host and Microbe</i> , 2021, 29, 322-324.	5.1	78
29	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	24
30	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab220.	0.4	33
31	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. <i>Cell Reports Medicine</i> , 2021, 2, 100290.	3.3	145
32	Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. <i>Cmaj</i> , 2021, 193, E793-E800.	0.9	40
33	SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study. <i>Canadian Journal of Public Health</i> , 2021, 112, 576-586.	1.1	18
34	Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. <i>Cell Host and Microbe</i> , 2021, 29, 904-916.e6.	5.1	29
35	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	5.1	173
36	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , 2021, 36, 109353.	2.9	95

#	ARTICLE	IF	CITATIONS
37	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021, 95, e0079621.	1.5	6
38	Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions. <i>Vaccines</i> , 2021, 9, 975.	2.1	5
39	Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells. <i>MBio</i> , 2021, 12, e0140521.	1.8	3
40	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <i>Immunity</i> , 2021, 54, 2143-2158.e15.	6.6	155
41	The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells. <i>Journal of Biological Chemistry</i> , 2021, 297, 101042.	1.6	11
42	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 2012-2024.	15.2	206
43	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <i>Journal of Biological Chemistry</i> , 2021, 297, 101151.	1.6	42
44	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. <i>Virology</i> , 2021, 563, 134-145.	1.1	74
45	A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells. <i>STAR Protocols</i> , 2021, 2, 100851.	0.5	28
46	HIV-1 Envelope Glycoprotein Cell Surface Localization Is Associated with Antibody-Induced Internalization. <i>Viruses</i> , 2021, 13, 1953.	1.5	2
47	HIV-1 Envelope Glycoproteins Proteolytic Cleavage Protects Infected Cells from ADCC Mediated by Plasma from Infected Individuals. <i>Viruses</i> , 2021, 13, 2236.	1.5	2
48	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	4.7	32
49	Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays. <i>Microbiology Spectrum</i> , 2021, 9, e0088621.	1.2	17
50	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	15.2	80
51	Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 371-378.	1.3	8
52	Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice. <i>Microorganisms</i> , 2020, 8, 1490.	1.6	1
53	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. <i>MBio</i> , 2020, 11, .	1.8	186
54	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. <i>Viruses</i> , 2020, 12, 1104.	1.5	29

#	ARTICLE	IF	CITATIONS
55	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. <i>Cell Reports Medicine</i> , 2020, 1, 100126.	3.3	200
56	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <i>Cell Host and Microbe</i> , 2020, 28, 880-891.e8.	5.1	153
57	Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site. <i>BMC Biology</i> , 2020, 18, 91.	1.7	20
58	Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 300-308.	1.5	15
59	Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. <i>Viruses</i> , 2020, 12, 1214.	1.5	26
60	Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells. <i>Microorganisms</i> , 2020, 8, 710.	1.6	7
61	The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. <i>MBio</i> , 2020, 11, .	1.8	37
62	Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	11
63	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. <i>EBioMedicine</i> , 2020, 54, 102727.	2.7	42
64	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2020, 94, .	1.5	28
65	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020, 27, 963-975.e5.	5.1	23
66	The Conformational States of the HIV-1 Envelope Glycoproteins. <i>Trends in Microbiology</i> , 2020, 28, 655-667.	3.5	66
67	Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. <i>Blood</i> , 2020, 136, 2588-2591.	0.6	127
68	Pharmacological Inhibition of PPAR γ Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection. <i>Pathogens and Immunity</i> , 2020, 5, 177.	1.4	12
69	Altered differentiation is central to HIV-specific CD4 ⁺ T cell dysfunction in progressive disease. <i>Nature Immunology</i> , 2019, 20, 1059-1070.	7.0	84
70	Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. <i>Cell Reports</i> , 2019, 29, 1449-1457.e5.	2.9	18
71	CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies. <i>Journal of Virology</i> , 2019, 93, .	1.5	29
72	Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. <i>Vaccines</i> , 2019, 7, 103.	2.1	15

#	ARTICLE	IF	CITATIONS
73	A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
74	Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses. <i>MBio</i> , 2019, 10, .	1.8	16
75	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	2.2	14
76	Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env. <i>Journal of Virology</i> , 2019, 93, .	1.5	32
77	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
78	An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Cell Host and Microbe</i> , 2019, 25, 578-587.e5.	5.1	93
79	Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. <i>Nature</i> , 2019, 568, 415-419.	13.7	156
80	Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
81	CD4 receptor diversity in chimpanzees protects against SIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3229-3238.	3.3	21
82	Identification of HIV gp41-specific antibodies that mediate killing of infected cells. <i>PLoS Pathogens</i> , 2019, 15, e1007572.	2.1	35
83	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. <i>MBio</i> , 2019, 10, .	1.8	17
84	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
85	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2019, 93, .	1.5	44
86	Exposing HIV-1 Env: Implications for therapeutic strategies. <i>Clinical and Investigative Medicine</i> , 2019, 42, E2-E6.	0.3	3
87	Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , 2018, 92, .	1.5	40
88	Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. <i>Virology</i> , 2018, 515, 38-45.	1.1	40
89	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Virology</i> , 2018, 92, .	1.5	56
90	Impact of HIV-1 Envelope Conformation on ADCC Responses. <i>Trends in Microbiology</i> , 2018, 26, 253-265.	3.5	64

#	ARTICLE	IF	CITATIONS
91	Antibody-dependent cellular cytotoxicity in HIV infection. <i>Aids</i> , 2018, 32, 2439-2451.	1.0	67
92	Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses. <i>Virology</i> , 2018, 521, 158-168.	1.1	11
93	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. <i>Journal of Immunology</i> , 2018, 201, 971-981.	0.4	50
94	5â€² Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. <i>Frontiers in Immunology</i> , 2018, 9, 628.	2.2	18
95	SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
96	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. <i>MBio</i> , 2018, 9, .	1.8	82
97	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. <i>Nature Communications</i> , 2018, 9, 2363.	5.8	46
98	Blocking HIV-1 replication: are Fcâ€³ receptor interactions required?. <i>Journal of Clinical Investigation</i> , 2018, 129, 53-54.	3.9	4
99	The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. <i>Journal of Virology</i> , 2017, 91, .	1.5	37
100	Beyond Viral Neutralization. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 760-764.	0.5	36
101	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	52
102	Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
103	BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
104	Effect of HIV-1 Env on SERINC5 Antagonism. <i>Journal of Virology</i> , 2017, 91, .	1.5	81
105	Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. <i>Journal of Virology</i> , 2017, 91, .	1.5	53
106	Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
107	Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region. <i>Structure</i> , 2017, 25, 1719-1731.e4.	1.6	31
108	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017, 13, 1115-1122.	3.9	110

#	ARTICLE	IF	CITATIONS
109	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. <i>Nature Protocols</i> , 2017, 12, 2029-2049.	5.5	55
110	Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 428-431.	0.5	26
111	HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes. <i>PLoS ONE</i> , 2017, 12, e0174550.	1.1	15
112	Unlocking HIV-1 Env: implications for antibody attack. <i>AIDS Research and Therapy</i> , 2017, 14, 42.	0.7	8
113	HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance. , 2017, , 545-557.		1
114	First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. <i>Retrovirology</i> , 2016, 13, 82.	0.9	21
115	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region. <i>Structure</i> , 2016, 24, 697-709.	1.6	46
116	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. <i>EBioMedicine</i> , 2016, 3, 122-134.	2.7	67
117	Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. <i>Cell Host and Microbe</i> , 2016, 20, 429-442.	5.1	154
118	A Highly Conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability. <i>Journal of Virology</i> , 2016, 90, 8395-8409.	1.5	15
119	Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2016, 90, 10065-10073.	1.5	6
120	Novel Acylguanidine-Based Inhibitor of HIV-1. <i>Journal of Virology</i> , 2016, 90, 9495-9508.	1.5	17
121	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. <i>Cell Host and Microbe</i> , 2016, 20, 368-380.	5.1	170
122	NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1089-1096.	0.5	31
123	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <i>EBioMedicine</i> , 2016, 12, 208-218.	2.7	65
124	A Highly Conserved Residue in HIV-1 Nef Alpha Helix 2 Modulates Protein Expression. <i>MSphere</i> , 2016, 1, .	1.3	12
125	Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240. <i>Scientific Reports</i> , 2016, 6, 36685.	1.6	31
126	Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. <i>MBio</i> , 2016, 7, .	1.8	131

#	ARTICLE	IF	CITATIONS
127	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. <i>Journal of Virology</i> , 2016, 90, 2127-2134.	1.5	69
128	HIV-1 Adapts To Replicate in Cells Expressing Common Marmoset APOBEC3G and BST2. <i>Journal of Virology</i> , 2016, 90, 725-740.	1.5	4
129	Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2016, 90, 2993-3002.	1.5	72
130	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. <i>Journal of Virology</i> , 2016, 90, 2021-2030.	1.5	53
131	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. <i>Viruses</i> , 2015, 7, 5115-5132.	1.5	42
132	Effects of the I559P gp41 Change on the Conformation and Function of the Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimer. <i>PLoS ONE</i> , 2015, 10, e0122111.	1.1	52
133	HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. <i>Journal of Virological Methods</i> , 2015, 215-216, 37-44.	1.0	21
134	CD4 mimetics sensitize HIV-1-infected cells to ADCC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2687-94.	3.3	118
135	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2015, 89, 545-551.	1.5	173
136	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
137	Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. <i>Journal of Virology</i> , 2015, 89, 10707-10711.	1.5	2
138	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. <i>Journal of Virology</i> , 2015, 89, 97-109.	1.5	42
139	Uncovering HIV-1-infected cells. <i>Oncotarget</i> , 2015, 6, 21791-21792.	0.8	2
140	Role of HIV-1 Envelope Glycoproteins Conformation and Accessory Proteins on ADCC Responses. <i>Current HIV Research</i> , 2015, 14, 9-23.	0.2	42
141	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. <i>Cell Host and Microbe</i> , 2014, 16, 711-721.	5.1	143
142	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2014, 88, 2633-2644.	1.5	237
143	Short Communication: Anti-HIV-1 Envelope Immunoglobulin Gs in Blood and Cervicovaginal Samples of Beninese Commercial Sex Workers. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1145-1149.	0.5	24
144	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. <i>Journal of Virological Methods</i> , 2014, 208, 107-114.	1.0	62

#	ARTICLE	IF	CITATIONS
145	A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. <i>Nature Chemical Biology</i> , 2014, 10, 845-852.	3.9	77
146	Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay. <i>Journal of Visualized Experiments</i> , 2014, , 51995.	0.2	36
147	The Highly Conserved Layer-3 Component of the HIV-1 gp120 Inner Domain Is Critical for CD4-Required Conformational Transitions. <i>Journal of Virology</i> , 2013, 87, 2549-2562.	1.5	49
148	The HIV-1 gp120 Major Variable Regions Modulate Cold Inactivation. <i>Journal of Virology</i> , 2013, 87, 4103-4111.	1.5	20
149	Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. <i>Cellular Microbiology</i> , 2013, 15, 809-822.	1.1	5
150	Virus-Specific Effects of TRIM5 α RING Domain Functions on Restriction of Retroviruses. <i>Journal of Virology</i> , 2013, 87, 7234-7245.	1.5	21
151	Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12438-12443.	3.3	101
152	Lineage-Specific Differences between Human and Simian Immunodeficiency Virus Regulation of gp120 Trimer Association and CD4 Binding. <i>Journal of Virology</i> , 2012, 86, 8974-8986.	1.5	30
153	Identification of interdependent variables that influence coreceptor switch in R5 SHIVSF162P3N-infected macaques. <i>Retrovirology</i> , 2012, 9, 106.	0.9	8
154	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5663-5668.	3.3	222
155	Adoption of an "Open" Envelope Conformation Facilitating CD4 Binding and Structural Remodeling Precedes Coreceptor Switch in R5 SHIV-Infected Macaques. <i>PLoS ONE</i> , 2011, 6, e21350.	1.1	18
156	An Inducible Cell-Cell Fusion System with Integrated Ability to Measure the Efficiency and Specificity of HIV-1 Entry Inhibitors. <i>PLoS ONE</i> , 2011, 6, e26731.	1.1	32
157	Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. <i>Journal of Virological Methods</i> , 2010, 168, 155-161.	1.0	35
158	Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5 α . <i>Virology</i> , 2010, 408, 204-212.	1.1	30
159	Species-Specific Inhibition of Foamy Viruses from South American Monkeys by New World Monkey TRIM5 α Proteins. <i>Journal of Virology</i> , 2010, 84, 4095-4099.	1.5	41
160	A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer. <i>Journal of Virology</i> , 2010, 84, 3147-3161.	1.5	64
161	Topological Layers in the HIV-1 gp120 Inner Domain Regulate gp41 Interaction and CD4-Triggered Conformational Transitions. <i>Molecular Cell</i> , 2010, 37, 656-667.	4.5	194
162	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. <i>Science</i> , 2010, 329, 811-817.	6.0	1,050

#	ARTICLE	IF	CITATIONS
163	A B-Box 2 Surface Patch Important for TRIM5 ^{1±} Self-Association, Capsid Binding Avidity, and Retrovirus Restriction. <i>Journal of Virology</i> , 2009, 83, 10737-10751.	1.5	145
164	Transitions to and from the CD4-Bound Conformation Are Modulated by a Single-Residue Change in the Human Immunodeficiency Virus Type 1 gp120 Inner Domain. <i>Journal of Virology</i> , 2009, 83, 8364-8378.	1.5	57
165	Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation. <i>Journal of Virology</i> , 2009, 83, 4476-4488.	1.5	50
166	HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4AVPRBP E3 Ubiquitin Ligase. <i>PLoS Pathogens</i> , 2007, 3, e85.	2.1	175
167	Productive Human Immunodeficiency Virus Type 1 Assembly Takes Place at the Plasma Membrane. <i>Journal of Virology</i> , 2007, 81, 7476-7490.	1.5	97
168	Major Histocompatibility Complex Class II Molecules Promote Human Immunodeficiency Virus Type 1 Assembly and Budding to Late Endosomal/Multivesicular Body Compartments. <i>Journal of Virology</i> , 2006, 80, 9789-9797.	1.5	27
169	Role of CD4 Receptor Down-regulation During HIV-1 Infection. <i>Current HIV Research</i> , 2004, 2, 51-59.	0.2	71
170	Two-step purification of His-tagged Nef protein in native condition using heparin and immobilized metal ion affinity chromatographies. <i>Journal of Virological Methods</i> , 2003, 111, 69-73.	1.0	19
171	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7